MedTrace Logo

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04350190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-01-13

No results posted yet for this study

Summary

The study is to evaluate the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including The Overall Response Rate (ORR), Progression-free survival (PFS),Overall survival (OS),and Toxicities.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Apatinib mesylate tablet

The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.

DRUG

PD-1

The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.

Sponsors & Collaborators

  • Wuzhou Red Cross Hospital

    collaborator OTHER

  • Guangxi Naxishan Hospital

    collaborator OTHER

  • Laibin People's Hospital

    collaborator OTHER

  • People's Hospital of Lingshan

    collaborator UNKNOWN

  • Wei Jiang

    lead OTHER

Principal Investigators

  • Wei Jiang, Ph.D. · Guilin Medical University, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2022-09-15
Completion
2022-09-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04350190 on ClinicalTrials.gov